EVANSTON, Ill., Jan. 9, 2014 /PRNewswire/ -- Naurex Inc. today announced that Norbert G. Riedel, Ph.D., long-term board member and newly-appointed president and chief executive officer of Naurex, will present at the 32nd Annual J.P. Morgan Healthcare Conference at 3 p.m. PST on Tuesday, January 14, 2014 at the Westin St. Francis Hotel in San Francisco. Dr. Riedel will provide an overview of the company and discuss its two clinical-stage rapid-acting antidepressant drug candidates, GLYX-13 and NRX-1074.
About Naurex
Naurex is a clinical-stage biopharmaceutical company developing products to treat diseases of the central nervous system (CNS). The company's lead compound, GLYX-13, has shown promising rapid-acting antidepressant activity with excellent safety and no psychomimetic side effects in a Phase 2a clinical trial. GLYX-13 is currently in a Phase 2b repeat dose study as adjunctive therapy for major depressive disorder. Naurex's 2nd-generation antidepressant, NRX-1074, is in Phase 1 clinical trials. Naurex's proprietary platform is focused on discovering novel compounds that act at the NMDA receptor to modulate neuronal plasticity and hold therapeutic potential for a number of CNS indications. For more information, visitwww.naurex.com.
Contacts:
Naurex Inc.
Ashish Khanna
Vice President, Corporate Development
T: 847-871-0377
corporate@naurex.com
Media and Investors
Russo Partners, LLC
Robert Flamm, Ph.D.
Matt Middleman, M.D.
T: 212-845-4226
T: 212-845-4272
robert.flamm@russopartnersllc.com
matt.middleman@russopartnersllc.com
SOURCE Naurex Inc.
